CDC- BRFSS – ACBS 18-20 Child Prevalence Table 8

Table 8: Estimated percent using inhaled short acting beta agonists among children1 with current2 asthma status by state/territory – BRFSS Asthma Call-back Survey, United States, 2018-2020.
State/Territory Current
Sample
size±
% SE§ 95% CI
California 68 57.7 8.3 (41.4 – 74.0)
Connecticut 149 51.4 6.5 (38.7 – 64.1)
Florida 133 31.7 7.0 (18.0 – 45.4)
Hawaii 66 37.3 7.6 (22.4 – 52.2)
Indiana 94 53.4 6.7 (40.3 – 66.5)
Kansas 107 44.1 5.7 (32.9 – 55.3)
Michigan 183 49.3 4.6 (40.3 – 58.3)
Minnesota 165 44.7 5.5 (33.9 – 55.5)
Missouri 87 62.3 7.4 (47.8 – 76.8)
Montana 59 50.1 8.5 (33.4 – 66.8)
Nebraska 127 52.4 6.6 (39.5 – 65.3)
New Hampshire 67 41.2 7.9 (25.7 – 56.7)
New Mexico 73 52.4 9.1 (34.6 – 70.2)
New York 68 36.4 8.0 (20.7 – 52.1)
Ohio 124 54.0 6.9 (40.5 – 67.5)
Oregon 56 57.5 13.0 (32.0 – 83.0)
Pennsylvania 70 51.9 7.9 (36.4 – 67.4)
Rhode Island 52 53.1 9.1 (35.3 – 70.9)
Texas 121 64.3 8.0 (48.6 – 80.0)
Utah 188 48.0 4.7 (38.8 – 57.2)
Vermont 108 68.1 5.5 (57.3 – 78.9)
Wisconsin 68 45.8 8.2 (29.7 – 61.9)
Puerto Rico 114 14.4 3.4 (7.7 – 21.1)
24 States / Area 2,448 50.5 2.6 (45.4 – 55.6)
Median 50.8
Range 14.4-68.1

1 Aged < 18 years

2 “Yes” response to “Do you still have asthma?”

± Sample size for multiple years of participation. Responses of “Don’t Know” and “Refused” are excluded.

§ Standard error

Confidence interval

Link for Summary Data Quality Report: https://www.cdc.gov/brfss/acbs/2020/pdf/sdq_report_acbs_20-508.pdf